Search

Your search keyword '"Schaap, Jeroen"' showing total 232 results

Search Constraints

Start Over You searched for: Author "Schaap, Jeroen" Remove constraint Author: "Schaap, Jeroen"
232 results on '"Schaap, Jeroen"'

Search Results

6. Contemporary guideline‐directed medical therapy in de novo, chronic, and worsening heart failure patients: First data from the TITRATE‐HF study

7. Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients with Melanoma Treated with Pembrolizumab

8. Safety of the oral factor XIa inhibitor asundexian compared with apixaban in patients with atrial fibrillation (PACIFIC-AF): a multicentre, randomised, double-blind, double-dummy, dose-finding phase 2 study

11. RELEASE-HF study: a protocol for an observational, registry-based study on the effectiveness of telemedicine in heart failure in the Netherlands

13. Guideline implementation, drug sequencing, and quality of care in heart failure: design and rationale of TITRATE‐HF

16. 1-Year Outcomes of Delayed Versus Immediate Intervention in Patients With Transient ST-Segment Elevation Myocardial Infarction

17. The different risk of new‐onset, chronic, worsening, and advanced heart failure: A systematic review and meta‐regression analysis.

18. Guideline implementation, drug sequencing, and quality of care in heart failure: design and rationale of TITRATE‐HF.

19. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma.

23. Figure S1 from Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients with Melanoma Treated with Pembrolizumab

24. Table S1 from Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients with Melanoma Treated with Pembrolizumab

25. Figure Legends from Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients with Melanoma Treated with Pembrolizumab

26. Figure S1 from Phase I Study of Pembrolizumab (MK-3475; Anti–PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors

27. Supplementary Tables S1-2, Figure 1 from Phase I Study of Pembrolizumab (MK-3475; Anti–PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors

29. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial

30. Safety of the oral factor XIa inhibitor asundexian compared with apixaban in patients with atrial fibrillation (PACIFIC-AF): a multicentre, randomised, double-blind, double-dummy, dose-finding phase 2 study

33. CCTA for Improved Assessment of Patients with Acute Chest Pain and Non-Conclusive Elevated High-Sensitivity Troponins

34. Risk, Clinical Course, and Outcome of Ischemic Stroke in Patients Hospitalized With COVID-19: A Multicenter Cohort Study

35. Coronary CT angiography for improved assessment of patients with acute chest pain and low-range positive high-sensitivity troponins: study protocol for a prospective, observational, multicentre study (COURSE trial)

36. Drug Distribution in Brain and Cerebrospinal Fluids in Relation to IC50 Values in Aging and Alzheimer's Disease, Using the Physiologically Based LeiCNS-PK3.0 Model.

39. Omecamtiv mecarbil in chronic heart failure with reduced ejection fraction, GALACTIC‐HF: baseline characteristics and comparison with contemporary clinical trials

41. Colchicine in Patients with Chronic Coronary Disease

42. 814 MCLA-145 (CD137xPD-L1): a potent CD137 agonist and immune checkpoint inhibitor that that does not show signs of peripheral toxicity

43. [Untitled]

47. Diurnal modulation of pacemaker potentials and calcium current in the mammalian circadian clock

50. TEXT-MINING IN ELECTRONIC HEALTHCARE RECORDS FOR EFFICIENT RECRUITMENT AND DATA-COLLECTION IN CARDIOVASCULAR TRIALS: A MULTICENTER VALIDATION STUDY

Catalog

Books, media, physical & digital resources